Immunotherapy | Topics

VERSATILE-002 Trial to Enroll Previously Treated HPV+ HNSCC Per Protocol Amendment
June 03, 2021

A new treatment arm of a phase 2 trial examining PDS0101 plus pembrolizumab in patients with HPV-related head and neck cancers will be opened to patients with immune checkpoint inhibitor–pretreated disease.

High Tumor Mutation Burden Predicts Response to Immune Checkpoint Blockade for Some Cancer Types
April 03, 2021

Data investigating the predictive capabilities of high tumor mutation burden found it to be predictive of response to immune checkpoint blockade in some, but not all, types of cancers.

Updated Data Announced for Both COM701 Monotherapy and in Combination with Nivolumab
March 19, 2021

Compugen announced updated data surrounding the investigational therapeutic antibody, COM701, as monotherapy and in combination with nivolumab.